StockData
Bionano Genomics, Inc. logo

Bionano Genomics, Inc. (BNGO) company profile

BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3083% below fair value
$0.95+0.01 (+1.29%)

Close on Nov 17, 2026Market cap $11.21MP/E –Yield –

About Bionano Genomics

Laboratory Analytical Instruments, SIC 3826

Bionano Genomics, Inc. is a life sciences company that provides optical genome mapping solutions for genomic analysis and cytogenetic research. The company offers imaging instruments, notably the Saphyr and Stratys systems, along with related consumables, testing services, and VIA data analysis software. It conducts business through a single reportable segment and operates subsidiaries including BioDiscovery, Purigen Biosystems, and Lineagen, which operates as Bionano Laboratories. Its customers include researchers, cytogeneticists, and laboratories performing routine genomic analysis.

The company’s principal executive offices are located in San Diego, California, with additional facility operations in Pleasanton, California. Geographically, Bionano serves customers and delivers products across three primary regions: the Americas, Asia-Pacific, and Europe, the Middle East, and Africa. Its global operations rely on domestic and international sales channels alongside contract manufacturing partners and suppliers.

Summary of the business section of Bionano Genomics's latest annual report, written by StockData.

Company profile

Company

Legal name
Bionano Genomics, Inc.
Headquarters
San Diego, CA
Address
9540 Towne Centre Drive, Suite 100 92121
Phone
(858) 888-7600
Employees
97, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Diego, California

Stock & identifiers

Ticker
BNGO
Exchange
Nasdaq
IPO date
Aug 22, 2018
Shares outstanding
12M, Aug 6, 2026
Public float
$12.15M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-60 reverse, Jan 27, 2025; 1-for-10 reverse, Aug 7, 2023
SEC CIK
1411690
CUSIP
09075F404
ISIN
US09075F4046
FIGI
BBG001KWWRS9
Share class FIGI
BBG001V0SSM6
LEI
54930086AP7ROH0VJ631
EIN
26-1756290

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Albert LudererInterim Chief Executive, Director8,000
R. Erik HolmlinPRESIDENT AND CEO, Director1,665
Jonathan V. DixonGeneral Counsel239
Mark AdamchakPrincipal Accounting Officer253
Alex Reid HastieChief Scientific Officer63
Mark OldakowskiChief Operating Officer868
Alka ChaubeyCHIEF MEDICAL OFFICER620
Aleksandar RajkovicDirector0
Kristiina Vuori MDDirector0
Christopher J. TwomeyDirector74,500
David L. BarkerDirector58,364
Yvonne LinneyDirector0
Hannah MamuszkaDirector65,789

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.11M$1.01M$756.33K$0–
FY2024$989.68K$535.44K$662.64K$2–
FY2023$1.53M-$949.35K$1.03M$13–
FY2022$2.77M$740.06K$4.72M$48–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payTotalvs. prior year
R. Erik Holmlin, Ph.D.
Chief Executive Officer
$600.00K$55.43K$457.32K$1.11M+12%
Mark Oldakowski
Chief Operating Officer
$460.00K$22.13K$274.20K$756.33K+14%
Alka Chaubey, Ph.D., FACMG
Chief Medical Officer
$460.00K$22.13K$274.20K$756.33K+14%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 22, 2018
Offer price
$6.13
Securities offered
3,360,000
Gross proceeds
$20.58M
Exchange
Nasdaq
First trading day
Aug 21, 2018
First-day close
$6.15+0.4%
Lock-up ends (est.)
Feb 17, 2019

“Per Unit Total Initial public offering price $ 6.1250 $ 20,580,000 Underwriting discounts and commissions (1) $ 0.4288 $ 1,440,600 Proceeds to Bionano Genomics, Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 97 employees, 95 of whom were full-time employees and 2 of whom were part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?